Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Azenta Inc (AZTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: AZTA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $32.25
1 Year Target Price $32.25
| 1 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.46% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.44B USD | Price to earnings Ratio - | 1Y Target Price 32.25 |
Price to earnings Ratio - | 1Y Target Price 32.25 | ||
Volume (30-day avg) 7 | Beta 1.61 | 52 Weeks Range 23.91 - 63.58 | Updated Date 07/8/2025 |
52 Weeks Range 23.91 - 63.58 | Updated Date 07/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -9.77% | Operating Margin (TTM) -8.77% |
Management Effectiveness
Return on Assets (TTM) -1.66% | Return on Equity (TTM) -8.58% |
Valuation
Trailing PE - | Forward PE 29.07 | Enterprise Value 1164220702 | Price to Sales(TTM) 2.15 |
Enterprise Value 1164220702 | Price to Sales(TTM) 2.15 | ||
Enterprise Value to Revenue 1.74 | Enterprise Value to EBITDA 84.48 | Shares Outstanding 45779900 | Shares Floating 40102317 |
Shares Outstanding 45779900 | Shares Floating 40102317 | ||
Percent Insiders 1.79 | Percent Institutions 116.78 |
Upturn AI SWOT
Azenta Inc
Company Overview
History and Background
Azenta, Inc. (formerly Brooks Automation) was founded in 1978. Initially focused on automation solutions for the semiconductor industry, it has since evolved to focus on life sciences, particularly in sample management and genomics services. A significant shift occurred in 2021 when Brooks Automation divested its Automation Solutions Group to Thomas H. Lee Partners and rebranded as Azenta, Inc., solidifying its focus on life sciences.
Core Business Areas
- Genomics Services: Offers gene sequencing and gene synthesis. Also, services for cell line engineering and GMP manufacturing. Provides tools for researchers to outsource genomics workflows, thus, decreasing timeline, effort, and cost.
- Sample Management Solutions: Provides automated ultra-low temperature storage solutions to preserve biological samples in both automated and manual formats. Products can be utilized for sample preparation to downstream analyses. Also provides cloud-based information management solutions.
Leadership and Structure
Azenta Inc. is led by CEO Steve Schwartz. The company has a typical corporate structure with departments for finance, operations, marketing, and sales. It is headquartered in Burlington, Massachusetts.
Top Products and Market Share
Key Offerings
- Automated Storage Solutions: Provides automated cryogenic and ultra-low temperature storage for biological samples. This is a fragmented market with no single dominant player. Competitors include Thermo Fisher Scientific (TMO) and BioLife Solutions (BLFS). Market share is estimated to be ~20%.
- Genomics Services (Gene Sequencing & Synthesis): Offers genomics services, including gene sequencing, synthesis, and related services. This market is highly competitive with companies like Illumina (ILMN) and Thermo Fisher Scientific (TMO). Market share is estimated to be ~5-10%.
- Cell Line Development & Manufacturing: Offers both cell line engineering and GMP manufacturing to support various research and development and other commercial applications. Competitors include Thermo Fisher Scientific (TMO) and Lonza Group (LONN.SW). Market share is estimated to be ~5-10%.
Market Dynamics
Industry Overview
The life sciences industry is growing, driven by increased research and development spending, the rise of personalized medicine, and growing demand for biological sample management and genomic solutions. Key trends include automation, digitalization, and the integration of genomics into clinical practice.
Positioning
Azenta is positioned as a provider of sample management and genomics solutions for the life sciences industry. Its competitive advantage lies in its automated storage solutions and its growing genomics services offerings.
Total Addressable Market (TAM)
The total addressable market (TAM) for sample management and genomics solutions is estimated to be in the billions of dollars. Azenta is focused on capturing a larger share of this market through organic growth and acquisitions.
Upturn SWOT Analysis
Strengths
- Strong position in automated sample management solutions
- Growing genomics services business
- Focus on life sciences market
- Strong management team
Weaknesses
- Reliance on life sciences market
- Small relative to bigger players such as Thermo Fisher Scientific (TMO) and Illumina (ILMN)
- Lower margins compared to peers.
Opportunities
- Further expansion into genomics services
- Acquisitions of complementary businesses
- Partnerships with pharmaceutical and biotechnology companies
- Growing demand for biostorage solutions
Threats
- Competition from larger players
- Economic downturn
- Technological advancements that could disrupt the market
- Regulatory changes affecting the life sciences industry
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Illumina (ILMN)
- BioLife Solutions (BLFS)
Competitive Landscape
Azenta faces competition from larger, more established players such as Thermo Fisher Scientific and Illumina. Its advantage lies in its specialization in sample management and its growing genomics services offerings.
Major Acquisitions
Boca Scientific
- Year: 2021
- Acquisition Price (USD millions): 41
- Strategic Rationale: Expand capabilities and reach in the biosample supply chain
Growth Trajectory and Initiatives
Historical Growth: Azenta's growth has been driven by acquisitions and organic growth in its sample management and genomics services businesses.
Future Projections: Analyst estimates suggest continued revenue growth in the high single digits to low double digits.
Recent Initiatives: Recent strategic initiatives include acquisitions of companies in the genomics services space and expansion of its sample management solutions portfolio.
Summary
Azenta is a growing player in the life sciences market, focused on sample management and genomics services. It has a strong position in automated storage solutions and is expanding its genomics offerings. While facing competition from larger companies, Azenta's specialization and strategic acquisitions position it for continued growth. However, Azenta should manage integration risks from the acquisitions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Analyst Reports
- SEC Filings
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Azenta Inc
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 1995-02-02 | President, CEO & Director Mr. John P. Marotta | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 3000 | Website https://www.azenta.com |
Full time employees 3000 | Website https://www.azenta.com | ||
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in the United States, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates through three reportable segments: Sample Management Solutions, Multiomics, and B Medical Systems. The Sample Management Solutions segment provides sample management products and solutions, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, synthesis editing, and related services. The B Medical Systems segment manufactures and distributes temperature-controlled storage and transportation solutions to governments, health institutions, and non-government organizations. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.